404 related articles for article (PubMed ID: 31570105)
1. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.
Alunni-Fabbroni M; Rönsch K; Huber T; Cyran CC; Seidensticker M; Mayerle J; Pech M; Basu B; Verslype C; Benckert J; Malfertheiner P; Ricke J
J Transl Med; 2019 Oct; 17(1):328. PubMed ID: 31570105
[TBL] [Abstract][Full Text] [Related]
2. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
5. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.
Ng CKY; Di Costanzo GG; Tosti N; Paradiso V; Coto-Llerena M; Roscigno G; Perrina V; Quintavalle C; Boldanova T; Wieland S; Marino-Marsilia G; Lanzafame M; Quagliata L; Condorelli G; Matter MS; Tortora R; Heim MH; Terracciano LM; Piscuoglio S
Ann Oncol; 2018 May; 29(5):1286-1291. PubMed ID: 29509837
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA.
Hlady RA; Zhao X; Pan X; Yang JD; Ahmed F; Antwi SO; Giama NH; Patel T; Roberts LR; Liu C; Robertson KD
Theranostics; 2019; 9(24):7239-7250. PubMed ID: 31695765
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma.
Yan L; Chen Y; Zhou J; Zhao H; Zhang H; Wang G
Int J Infect Dis; 2018 Feb; 67():92-97. PubMed ID: 29229500
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma.
Cai ZX; Chen G; Zeng YY; Dong XQ; Lin MJ; Huang XH; Zhang D; Liu XL; Liu JF
Int J Cancer; 2017 Sep; 141(5):977-985. PubMed ID: 28543104
[TBL] [Abstract][Full Text] [Related]
9. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics.
Jiao J; Sanchez JI; Thompson EJ; Mao X; McCormick JB; Fisher-Hoch SP; Futreal PA; Zhang J; Beretta L
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299031
[TBL] [Abstract][Full Text] [Related]
10. Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma.
Park S; Lee EJ; Rim CH; Seong J
Yonsei Med J; 2018 Jun; 59(4):470-479. PubMed ID: 29749129
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment.
Sogbe M; Bilbao I; Marchese FP; Zazpe J; De Vito A; Pozuelo M; D'Avola D; Iñarrairaegui M; Berasain C; Arechederra M; Argemi J; Sangro B
Clin Mol Hepatol; 2024 Apr; 30(2):177-190. PubMed ID: 38163441
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.
Cai Z; Chen G; Zeng Y; Dong X; Li Z; Huang Y; Xin F; Qiu L; Xu H; Zhang W; Su X; Liu X; Liu J
Clin Cancer Res; 2019 Sep; 25(17):5284-5294. PubMed ID: 31217202
[TBL] [Abstract][Full Text] [Related]
13. Circulating DNA changes are predictive of disease progression after transarterial chemoembolization.
Sefrioui D; Verdier V; Savoye-Collet C; Beaussire L; Ghomadi S; Gangloff A; Goria O; Riachi G; Montialoux H; Schwarz L; Tuech JJ; Frebourg T; Michel P; Sarafan-Vasseur N; Di Fiore F
Int J Cancer; 2022 Feb; 150(3):532-541. PubMed ID: 34622951
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of Cell-Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy.
Muraoka M; Maekawa S; Katoh R; Komiyama Y; Nakakuki N; Takada H; Matsuda S; Suzuki Y; Sato M; Tatsumi A; Miura M; Amemiya F; Shindo H; Takano S; Fukasawa M; Yamauchi K; Yamaguchi T; Nakayama Y; Inoue T; Enomoto N
Hepatol Commun; 2021 Nov; 5(11):1927-1938. PubMed ID: 34558819
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.
Xu RH; Wei W; Krawczyk M; Wang W; Luo H; Flagg K; Yi S; Shi W; Quan Q; Li K; Zheng L; Zhang H; Caughey BA; Zhao Q; Hou J; Zhang R; Xu Y; Cai H; Li G; Hou R; Zhong Z; Lin D; Fu X; Zhu J; Duan Y; Yu M; Ying B; Zhang W; Wang J; Zhang E; Zhang C; Li O; Guo R; Carter H; Zhu JK; Hao X; Zhang K
Nat Mater; 2017 Nov; 16(11):1155-1161. PubMed ID: 29035356
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.
Ikeda S; Lim JS; Kurzrock R
Mol Cancer Ther; 2018 May; 17(5):1114-1122. PubMed ID: 29483209
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma.
Hu S; Liu Y; Yang Q; Chen L; Chai H; Xiao M; Qi C; Qiu W
Invest New Drugs; 2023 Jun; 41(3):532-538. PubMed ID: 37099161
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
Teufel M; Seidel H; Köchert K; Meinhardt G; Finn RS; Llovet JM; Bruix J
Gastroenterology; 2019 May; 156(6):1731-1741. PubMed ID: 30738047
[TBL] [Abstract][Full Text] [Related]
19. Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma.
Nakatsuka T; Nakagawa H; Hayata Y; Wake T; Yamada T; Nishibatake Kinoshita M; Nakagomi R; Sato M; Minami T; Uchino K; Enooku K; Kudo Y; Tanaka Y; Kishikawa T; Otsuka M; Tateishi R; Koike K
J Gastroenterol; 2021 May; 56(5):456-469. PubMed ID: 33712873
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
